Abbott Laboratories (ABT) Financials

$109.30

$0.51 (0.47%)

As on 04-Sep-2026 13:43EDT

Market cap

$201,832 Mln

Revenue (TTM)

$46,585 Mln

P/E Ratio

36.9

P/B Ratio

3.9

Div. Yield

2.2 %

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Operating Revenue	46,585.00	44,328.00	41,950.00	40,109.00	43,653.00	43,075.00
Cost of Revenue	20,123.00	19,721.00	20,625.00	20,072.00	21,330.00	19,861.00
Gross Profit	26,462.00	24,607.00	21,325.00	20,037.00	22,323.00	23,214.00
Operating Expenses	18,557.00	16,586.00	14,474.00	13,602.00	13,961.00	14,014.00
Operating Profit (EBIT)	7,932.00	8,048.00	6,825.00	6,435.00	8,362.00	9,200.00
Other Income	--	--	--	--	502.00	319.00
Profit before Tax	7,511.00	8,466.00	7,013.00	6,664.00	8,306.00	8,211.00
Provision for Tax	2,086.00	1,942.00	-6,389.00	941.00	1,373.00	1,140.00
Profit after Tax (Net Income)	5,425.00	6,524.00	13,402.00	5,723.00	6,933.00	7,071.00
Minority Interest	--	--	--	--	--	--
Consolidated Profit	3,420.00	6,524.00	13,402.00	5,723.00	6,933.00	7,071.00

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Shareholder's Funds	51,110.00	52,130.00	47,664.00	38,603.00	36,686.00	35,802.00
Minority Interest	--	--	--	--	219.00	222.00
Non-Current Liabilities	39,639.00	17,446.00	19,356.00	20,546.00	22,044.00	26,067.00
Current Liabilities	17,814.00	16,496.00	14,157.00	13,841.00	15,489.00	13,105.00
Total Liabilities	127,029.00	86,713.00	81,414.00	73,214.00	74,438.00	75,196.00

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Non-Current Assets	84,698.00	60,717.00	57,758.00	50,544.00	49,214.00	50,957.00
Current Assets	24,517.00	25,996.00	23,656.00	22,670.00	25,224.00	24,239.00
Total Assets	133,732.00	86,713.00	81,414.00	73,214.00	74,438.00	75,196.00
Total Debt*	32,608.00	15,067.00	15,275.00	15,873.00	17,946.00	19,251.00
Net Current Assets	--	9,500.00	9,499.00	8,829.00	9,735.00	11,134.00

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Cash From Operating Activities	--	9,566.00	8,558.00	7,261.00	9,581.00	10,533.00
Cash Flow from Investing Activities	--	-2,422.00	-2,338.00	-3,133.00	-1,740.00	-2,008.00
Cash from Financing Activities	--	-6,309.00	-5,404.00	-7,091.00	-7,636.00	-5,494.00
Net Cash Inflow / Outflow	--	--	--	--	205.00	3,031.00

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Adjusted EPS ($)	3.11	3.73	7.68	3.27	3.95	3.97
Cash EPS ($)	--	5.52	9.52	5.13	5.10	5.12
Adjusted Book Value ($)	--	29.84	27.30	22.08	20.92	20.09
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	5.48	4.90	4.15	5.46	5.91
Free Cash Flow per Share ($)	--	4.23	3.64	2.89	4.45	4.85

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
ROCE (%)	--	10.03	22.83	10.49	12.64	13.13
ROE (%)	10.51	13.07	31.07	15.20	19.13	20.62
ROA (%)	4.69	7.76	17.33	7.75	9.27	9.57
EBIT Margin (%)	13.35	19.87	18.15	18.35	19.75	20.01
Net Margin (%)	11.65	14.72	31.95	14.27	15.70	16.29
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Revenue Growth (%)	8.06	0.06	0.05	-0.08	0.01	0.24
EBIT Growth (%)	-26.60	15.64	3.45	-14.60	--	51.89
Net Profit Growth (%)	-61.19	-51.32	134.18	-17.45	-1.95	57.31
EPS Growth (%)	-61.19	-0.51	1.34	-0.17	0.00	0.58
Book Value Growth (%)	1.54	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Price / Earnings	36.91	33.55	14.74	33.62	27.78	35.47
Price / Book Value	3.86	4.20	4.14	4.98	5.25	7.01
Dividend Yield (%)	2.17	--	--	--	--	--
EV/EBITDA	19.15	19.48	18.90	18.95	16.85	21.37
Close Price ($)	90.74	125.29	113.11	110.07	109.79	140.74
High Price ($)	137.49	141.23	121.64	115.83	141.77	142.60
Low Price ($)	81.97	110.86	99.71	89.67	93.25	105.36
Market Cap ($ Cr)	201,831.91	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Debt to Equity	--	0.29	0.32	0.41	0.49	0.54
Short term debt to equity ratio	0.06	0.06	0.04	0.03	0.07	0.03
Current Ratio	1.38	1.58	1.67	1.64	1.63	1.85
Quick Ratio	0.97	1.18	1.23	1.16	1.23	1.46
Interest Coverage	12.79	25.83	12.63	10.55	27.37	21.03

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Debtors to sales (%)	18.46	17.89	16.51	16.37	14.24	15.06
Asset Turnover	0.40	0.53	0.54	0.54	0.58	0.58
Receivable days	--	61.20	58.73	58.20	53.15	54.70
Inventory Days	--	117.44	113.02	115.94	97.01	93.51
Payable days	--	78.11	75.18	80.99	77.19	76.82
Cash Conversion Cycle	--	100.53	96.57	93.15	72.97	71.39

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Income Statement ($ Mln)